1 Department of Critical Care Medicine, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.
2 Department of Pediatrics, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.
J Neurotrauma. 2019 Jan 15;36(2):360-369. doi: 10.1089/neu.2018.5664. Epub 2018 Sep 5.
High mobility group box 1 (HMGB1) is a prototypical danger-associated molecular pattern molecule that is considered a late mediator of neuro-inflammation after traumatic brain injury (TBI). Prior studies have suggested that targeting HMGB1 may lead to neuroprotective effects, but none of these studies have reported cognitive outcomes. We hypothesized that loss of HMGB1 before and after TBI would markedly attenuate post-traumatic brain edema, blood-brain barrier (BBB) permeability, improve functional deficits and long-term neuropathology versus control mice. Using the controlled cortical impact model and conditional global HMGB1 knockout (HMGB1 KO) mice, we demonstrate that there was a neuroprotective effect seen in the HMGB1 KO versus wild-type control evidenced by a significant reduction in contusion volume. However, two surprising findings were 1) the lack of benefit on either post-traumatic brain edema or BBB permeability, and 2) that spatial memory performance was impaired in HMGB1 KO naïve mice such that the behavioral effects of HMGB1 deletion in uninjured naïve mice were similar to those observed after TBI. Our data suggest the possibility that the role of HMGB1 in TBI is a "double-edged sword"; that is, despite the benefits on selected aspects of secondary injury, the sustained absence of HMGB1 may impair cognitive function, even in naïve mice. Given the pleiotropic actions of extracellular and intracellular HMGB1, when evaluating the potential use of therapies targeting HMGB1, effects on long-term cognitive outcome should be carefully evaluated. It also may be prudent in future studies to examine cell-specific effects of manipulating the HMGB1 pathway.
高迁移率族蛋白 B1(HMGB1)是一种典型的危险相关分子模式分子,被认为是创伤性脑损伤(TBI)后神经炎症的晚期介质。先前的研究表明,靶向 HMGB1 可能导致神经保护作用,但这些研究均未报告认知结果。我们假设,TBI 前后 HMGB1 的缺失将显著减轻创伤后脑水肿、血脑屏障(BBB)通透性,改善功能缺陷和长期神经病理学,与对照小鼠相比。我们使用皮质控制撞击模型和条件性全局 HMGB1 敲除(HMGB1 KO)小鼠,证明与野生型对照相比,HMGB1 KO 中存在神经保护作用,表现为挫伤体积显著减小。然而,有两个令人惊讶的发现:1)HMGB1 KO 在创伤后脑水肿或 BBB 通透性方面缺乏益处,2)HMGB1 KO 未受伤的小鼠空间记忆表现受损,以至于 HMGB1 缺失对未受伤的小鼠的行为影响与 TBI 后观察到的相似。我们的数据表明,HMGB1 在 TBI 中的作用可能是一把“双刃剑”;也就是说,尽管对继发性损伤的某些方面有好处,但 HMGB1 的持续缺失可能会损害认知功能,即使是在未受伤的小鼠中也是如此。鉴于细胞外和细胞内 HMGB1 的多效性作用,在评估针对 HMGB1 的潜在治疗方法的使用时,应仔细评估对长期认知结果的影响。在未来的研究中,检查操纵 HMGB1 途径的细胞特异性效应可能也是谨慎的。